1. Introduction
===============

Congenital heart disease (CHD) is the most common congenital malformation, caused by abnormal development of great vessels and the fetal heart.^\[[@R1]\]^ CHD is the most common birth defects in human disease and is the main cause of death in infant\'s noninfectious diseases.^\[[@R2]\]^ It affects nearly 8 per 1000 live births in America,^\[[@R3]\]^ whereas the incidence increased sharply from 1.2 to 5.4 per 1000 live births between 2000 and 2011 in China, making it the number one killer among all birth defects.^\[[@R4]\]^ Although rapid advance has been made in drug therapy and surgical treatment during the several decades, the mortality of patients with CHD remained significantly increasing, and its related complications such as sudden cardiac death, arrhythmia, or heart failure may occur even after effective treatment.^\[[@R5],[@R6]\]^

To date, more and more genetic studies showed that CHD had significant genetic basis.^\[[@R7]\]^ Pathogenic gene mutations, microRNA lesion, and chromosomal aberrations could all lead to CHD.^\[[@R8]\]^ Therefore, it is important to identify the effect of genetic defects on CHD formations. Moreover, many genes related to CHD have been identified in genetics research, and transcription factors coded by most of these genes, such as GATA4, NKX2--5, TBX5, and TBX20, could regulate heart development.^\[[@R9]--[@R11]\]^ Recently, an increasing number of mutations in these genes have been identified in CHD patients,^\[[@R12],[@R13]\]^ suggesting their potential roles in CHD development.

GATA4 belongs to the GATA family of zinc finger transcription factors, which consists of 6 members, GATA1 to GATA6.^\[[@R14]\]^ Members of this family could identify the GATA motif presenting in the promoters of many genes. Therefore, these proteins could regulate genes involved in embryogenesis and in myocardial differentiation. GATA1, GATA2, and GATA3 are mainly expressed in the hematopoietic cells, whereas GATA4, GATA5, and GATA6 are predominantly expressed in tissues such as the heart, gonads, and liver.^\[[@R15]\]^ GATA4 expression during cardiac development is essential for proper cardiovascular formation and function. GATA4 inactivation, with GATA4-null mice, results in the formation of congenital cardiac defects including myocardial hypoplasia, double outlets of the right ventricle, and common atrioventricular canal.^\[[@R16]\]^ Moreover, *GATA4* mutations can lead to many kinds of human CHDs.^\[[@R17]\]^ So far, \>90 mutations of *GATA4* gene have been reported in CHD patients,^\[[@R18]\]^ and abnormal expression levels of GATA4 were also found to be associated with multiple cardiac defects.^\[[@R19]\]^

A growing number of studies have been done to identify the *GATA4* mutations in CHD; however, no meta-analysis is found to report the association between *GATA4* mutations and CHD. Several studies reported 3 mutations of *GATA4* in CHD, 99 G\>T, 487 C\>T, and 354 A\>C.^\[[@R20]--[@R30]\]^ Therefore, we performed a meta-analysis to assess the associations between *GATA4* 99 G\>T, 487 C\>T, or 354 A\>C mutations and the risk of CHD.

2. Materials and methods
========================

This meta-analysis was approved by the institutional review board of Henan Provincal People\'s Hospital. A systematic search of the electronic databases including PubMed, Embase, ISI, CNKI, and Wang fang was performed to screen eligible articles. The key words used to retrieve related literatures were as follows: "GATA4," "congenital heart defect," "congenital heart disease," "congenital cardiovascular malformation," "mutations," and "variants."

2.1. Inclusion criteria
-----------------------

The inclusion standards are as follows: studies that have been published as a full test; case-control studies containing CHD patients and healthy controls; studies that investigate the relationship of GATA4 mutations and CHD; studies that evaluate the GATA4 99 G\>T, 487 C\>T, or 354 A\>C variants and CHD risk. The excluded standards are as follows: duplicate publications; studies without available data; reviews, letters, case reports, and expert opinions.

2.2. Data extraction
--------------------

The extracted data included the first author, publication year, country of origin, ethnicity, sex, number of patient cases and controls, types of mutations, and types of CHD. Two investigators performed the data extraction independently. Any discrepancies between 2 investigators were resolved by discussion until reaching a consensus.

2.3. Statistical methods
------------------------

We used a random- or fixed-effects model to estimate the odds ratios (ORs) with 95% confidence intervals (95% CIs) by RevMan (version 5).^\[[@R31]\]^ The heterogeneity of the studies was evaluated by the *χ*^2^ value and the *I*^*2*^ value. Significant heterogeneity was defined as a *χ*^2^ test *P* \< .10 or as an *I*^*2*^ \>50%.^\[[@R32]\]^ If *I*^*2*^ ≤50%, a fixed-effects model was used for analysis. If not (*I*^*2*^ \>50%), a random-effects model was used. Subgroup analysis was performed based on sample size, ethnicity, and types of CHD. The types of CHD included ventricular septal defects (VSD), atrial septal defect, and others. The study was regarded as large-sample-size if the number of case is \>150; otherwise, the study was defined as small-sample-size according to previous studies ^\[[@R33],[@R34]\]^. To determine whether the results could be driven by one specific study, we conducted the sensitivity analysis by removing one study each time. Visual assessment of a funnel plot was used to estimate possible publication bias.^\[[@R35]\]^

3. Results
==========

3.1. Study selection
--------------------

A total of 72 records were obtained for this meta-analysis through electronic searches. The process of literature retrieval is presented in Figure [1](#F1){ref-type="fig"}. Fifty-two records were excluded because of reviews, duplicates, letters, case reports, and expert opinions. The remaining 20 full-text articles were examined in detail. Nine of these full-text articles were excluded. Finally, 11 studies were included in the meta-analysis. The characteristics of 11 eligible studies with 6217 participants were shown in Table [1](#T1){ref-type="table"}. Of the 11 studies,^\[[@R20]--[@R30]\]^ 7 were from Asian populations,^\[[@R21],[@R22],[@R25]--[@R27],[@R29],[@R30]\]^ and 4 studies were from whites. ^\[[@R20],[@R23],[@R24],[@R28]\]^ The earliest study was in June 2007,^\[[@R23]\]^ whereas the latest study was in May 2015.^\[[@R29]\]^ The number of patient cases ranged from 12 to 628, and the number of control cases was from 100 to 957.

![The flow chart of study selection procedure in the meta-analysis.](medi-96-e6857-g001){#F1}
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Characteristics of included studies in our meta-analysis.
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3.2. *GATA4* 99 G\>T mutation and CHD risk
------------------------------------------

The associations of *GATA4* 99 G\>T mutation with CHD risk were shown in Figure [2](#F2){ref-type="fig"}. Six studies, including 1863 patients and 1073 controls, were analyzed for associations between the 99 G\>T mutations of *GATA4* and CHD. As there was no significant heterogeneity (*P* for the heterogeneity = 0.90, *I*^*2*^ = 0%), a fixed-effects model was applied. No significant association of *GATA4* 99 G\>T mutation with the risk of CHD was found (OR = 1.22, 95% CI = 0.74--2.01, *P* = .43) (Fig. [2](#F2){ref-type="fig"}).

![The association of *GATA4* 99 G\>T mutation with the risk of congenital heart disease. Notes: The squares and horizontal lines represent odds ratio and 95% CI. The diamonds represent the pooled odds ratio and 95% CI. CI = confidence interval.](medi-96-e6857-g003){#F2}

3.3. *GATA4* 487 C\>T mutation and CHD risk
-------------------------------------------

The associations of *GATA4* 487 C\>T mutation with CHD risk were reported in Figure [3](#F3){ref-type="fig"}. Five studies including 1249 patients and 2271 controls were analyzed. A fixed-effects model was used because of no significant heterogeneity (*P* for the heterogeneity = .19, *I*^*2*^ = 35%). There was no significant association between *GATA4* 487 C\>T mutation and CHD risk (OR = 1.16, 95% CI = 0.48--2.78, *P* = .74) (Fig. [3](#F3){ref-type="fig"}).

![The association of *GATA4* 487 C\>T mutation with congenital heart disease risk. CI = confidence interval.](medi-96-e6857-g004){#F3}

3.4. *GATA4* 354 A\>C mutation and CHD risk
-------------------------------------------

The associations between *GATA4* 354 A\>C mutation and CHD risk were indicated in Figure [4](#F4){ref-type="fig"}. Three studies, including 524 patients and 709 controls, were analyzed. A fixed-effects model was used because of no significant heterogeneity (*P* for the heterogeneity = .20, *I*^*2*^ = 38%). *GATA4* 354 A\>C mutation was significantly associated with CHD risk (OR = 1.49, 95% CI = 1.15--1.93, *P* = .003) (Fig. [4](#F4){ref-type="fig"}).

![The association of GATA4 354 A\>C mutation with congenital heart disease risk.](medi-96-e6857-g005){#F4}

3.5. Subgroup analysis
----------------------

For *GATA4* 99 G\>T mutation and CHD risk, subgroup analysis was performed based on sample size and ethnicity. In the large-sample-size and small-sample-size subgroups, no significant association for *GATA4* 99 G\>T mutation was found (large-sample-size, OR = 1.08, 95% CI = 0.42--2.80, *P* = .87; small-sample-size, OR = 1.28, 95% CI = 0.71--2.30, *P* = .41) (Table [2](#T2){ref-type="table"}). In addition, there was no significant association between *GATA4* 99 G\>T mutation and the risk of CHD in the Asian and white subgroups (Asian, OR = 1.29, 95% CI = 0.77--2.16, *P* = .33; white, OR = 0.44, 95% CI = 0.06--3.38, *P* = .43) (Table [2](#T2){ref-type="table"}).

###### 

Subgroup analysis for *GATA4* 99 G\>T, 487 C\>T, and 354 A\>C mutations and CHD risk.
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For *GATA4* 487 C\>T mutation and CHD risk, subgroup analysis was carried out by stratifying available data based on sample size and ethnicity. In the large-sample-size and small-sample-size subgroups, we failed to detect any significant association for *GATA4* 487 C\>T mutation (large-sample-size, OR = 0.67, 95% CI = 0.22--2.08, *P* = .49; small-sample-size, OR = 4.30, 95% CI = 0.66--27.82, *P* = .13) (Table [2](#T2){ref-type="table"}). In addition, no significant association was found between *GATA4* 487 C\>T mutation and CHD risk in the Asian subgroup (OR = 0.90, 95% CI = 0.34--2.33, *P* = .82) (Table [2](#T2){ref-type="table"}).

For *GATA4* 354 A\>C mutation and CHD risk, subgroup analysis was also conducted by stratifying available data based on sample size, ethnicity, and types of CHD. In the large-sample-size subgroups, a significant association between *GATA4* 354 C\>T mutation and CHD risk was found (large-sample-size, OR = 1.41, 95% CI = 1.10--1.87, *P* = .007) (Table [2](#T2){ref-type="table"}). In addition, significant association was found between *GATA4* 354 C\>T mutation and CHD risk in the Asian subgroup (OR = 1.41, 95% CI = 1.10--1.87, *P* = .007) (Table [2](#T2){ref-type="table"}). However, no statistical evidence for the association between *GATA4* 354 C\>T mutation and VSD was detected (OR = 1.15, 95% CI = 0.82--1.62, *P* = .42) (Table [2](#T2){ref-type="table"}).

3.6. Sensitivity analysis
-------------------------

To determine whether the results could be driven by one specific study, we conducted the sensitivity analysis by removing one study each time. For *GATA4* 99 G\>T, 487 C\>T and 354 A\>C mutations, the sensitivity analysis indicated that none of the studies significantly affected the results.

3.7. Publication bias
---------------------

Visual inspection of funnel plots shown in Figures [5](#F5){ref-type="fig"}--[7](#F7){ref-type="fig"} revealed a slight asymmetry for *GATA4* 99 G\>T, 487 C\>T, and 354 A\>C mutations. These results suggested that there was no obvious publication bias among these studies.

![Funnel plot of publication bias for *GATA4* 99 G\>T mutation with the risk of congenital heart disease.](medi-96-e6857-g007){#F5}

![Funnel plot of publication bias for *GATA4* 487 C\>T mutation with congenital heart disease risk.](medi-96-e6857-g008){#F6}

![Funnel plot of publication bias for GATA4 354 A\>C mutation with congenital heart disease risk.](medi-96-e6857-g009){#F7}

4. Discussion
=============

The present meta-analysis suggested that *GATA4* 99 G\>T and 487 C\>T mutations may not be associated with CHD risk, whereas 354 A\>C mutations of *GATA4* gene was significantly associated with CHD risk. Moreover, no significant association of *GATA4* 99 G\>T and 487 C\>T mutations with the risk of CHD were detected by different sample size and ethnic groups. There was also no significant association between *GATA4* 354 A\>C mutation and VSD. However, *GATA4* 354 A\>C mutations were significantly associated with CHD risk in large sample size and Asian subgroups. Furthermore, the stability of our study was well supported by the sensitivity analysis and publication bias. In addition, no obvious heterogeneity was observed in the overall analysis and the subgroup analysis.

GATA4, a cardiac transcription factor, is well acknowledged as a critical regulator of gene expression and cellular activity in heart development.^\[[@R36]\]^ The coding region of GATA4 includes 2 transactivation domains, a nuclear localization signal, and 2 forms of type IV zinc-finger motif, and the C-terminal zinc finger motif of GATA4 could interact with transcription factors to regulate the expression of cardiac genes.^\[[@R37]\]^*GATA4* gene deletions, as well as gene duplications, have been reported to be related to CHD.^\[[@R38]\]^ In addition, many *GATA4* gene mutations associated with CHD were reported, which may contribute to the pathogenesis of CHD. Zhang et al^\[[@R18]\]^ reported a novel *GATA4* mutation, c.C931T (p.R311W), decreased the ability of GATA4 to activate its downstream target gene. A previous study reported another *GATA4* mutation, p.R43W, and the mutant protein resulted in a significant suppression in transcriptional activity.^\[[@R17]\]^ In a recent study, common mutations in a specific region of *GATA4* 3' UTR may lead to CHD susceptibility, likely by changing the miRNA posttranscriptional gene regulation.^\[[@R39]\]^ These studies indicated that *GATA4* gene mutations could contribute to the susceptibility of CHD.

Mounting studies have found more and more GATA4 mutations in CHD, including *GATA4* 99 G\>T, 487 C\>T, and 354 A\>C mutations.^\[[@R20],[@R22],[@R24],[@R26]--[@R30]\]^ Although these mutations have been identified, their association with CHD risk remains undefined. Moreover, there is no meta-analysis to assess the association between *GATA4* mutations and CHD risk. Considering that *GATA4* 99 G\>T, 487 C\>T, and 354 A\>C mutations were reported in several studies, we performed this meta-analysis to explore the association between these 3 mutations and CHD. For the 99 G\>T mutation, our overall results indicated that this mutation may not be associated with CHD risk, which was consistent with several previous studies.^\[[@R21],[@R25]\]^ For instance, Wang et al^\[[@R25]\]^ indicated no significant association between this mutation and CHD risk. In addition, no document reported the role of this mutation in CHD yet, which may because of the fact that 99 G\>T mutation has no effect on the amino acid sequence. For another mutation 487 C\>T, no association of this variant with CHD was found, which suggested that 487 C\>T mutation may not lead to the susceptibility of CHD. Moreover, 354 A\>C mutation was found to be closely related to the incidence of CHD, consistent with previous studies.^\[[@R29],[@R30]\]^ However, the result should be treated with caution because of lack of sufficient studies.

Subgroup analyses were performed based on sample size and ethnicity of study population. Furthermore, the sensitivity analysis implied that no single study significantly affected the results. In addition, no obvious publication bias was observed among these studies. All these analyses suggested our results were robust.

Several limitations in our study should be taken into consideration when construing the findings. First, the number of involved studies on *GATA4* 99 G\>T, 487 C\>T, and 354 A\>C mutations was limited. Second, we did not well describe the association of 99 G\>T, 487 C\>T, and 354 A\>C mutations with clinical stage of CHD and time to developing CHD owing to lack of data. Third, gene-environmental and gene-gene interactions could influence the associations of certain *GATA4* mutation with CHD. Certain site mutation may increase the CHD susceptibility, but interactions with multiple genes and environmental factors may lead to the absence of the association. Therefore, these factors should be taken into account to draw a more accurate conclusion. However, the information of other genes and environment factors including age, smoking, and alcohol are lack of enough data to analyze. Owing to these limitations, the results presented by the present study should be interpreted with caution.

In summary, the current meta-analysis first explored the association between GATA4 mutations and CHD risk. The results suggested that *GATA4* 99 G\>T and 487 C\>T mutations may not contribute to the pathogenesis of CHD, whereas 354 A\>C mutation was significantly associated with the risk of CHD. However, considering that the present results are based on limited number of studies, further researches with more published studies are needed to confirm our results. In addition, given that GATA4 plays a crucial role in heart development, further researches are needed to explore the potential role of other mutations of *GATA4* in the development of CHD.

Abbreviations: ASD = atrial septal defect, CHD = congenital heart disease, CI = confidence interval, ORs = Odds ratios, VSD = ventricular septal defects.
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